Uveal melanoma

Uveal melanoma is a very rare form of cancer that affects the eye. It starts in pigment cells (melanocytes) that are found either in the iris, muscle fibres behind the iris (ciliary body) or the blood vessels to the eye (choroid). These areas together are known as the uvea.

“Uveal melanoma is now classified as a distinct disease entity (rather than a different form of cutaneous melanoma) and has been granted ‘orphan status’ which means that there are some incentives to encourage new medicines to be developed. It is an exciting time for uveal melanoma as there are new treatments in development which will hopefully be available outside of clinical trials soon.” Professor Paul Nathan, Trustee (Consultant Medical Oncologist, Mount Vernon Cancer Centre)

 

If you would like a booklet sent directly to you, please email info@melanomafocus.org

uveal melanoma patient guide cover
Download full guide

Types of uveal melanoma

Uveal melanoma is sometimes named by where it is located in the eye:

  • Choroidal melanoma – This occurs in the blood vessels at the back of your eye. It is the most common form of uveal melanoma
  • Ciliary melanoma – This occurs in the ring of muscle fibres behind your iris that help the lens change shape for eye focus
  • Iris melanoma – This occurs in the iris – the area at the front of your eye that gives you your eye colour. It accounts for only 5% of all uveal melanomas and is often smaller and less likely to spread than the other forms

NB: Conjunctival melanoma is cancer that starts in the outer layer (conjunctiva) of the eye. It has more in common with skin melanoma and is not an uveal melanoma, and not covered here.

What are the causes?

The causes of uveal melanoma remain largely unknown. Unlike other types of melanoma, it is NOT linked with harmful sun exposure (some research links it to iris melanoma). However, there have been certain factors shown to could increase your risk. These include having fair skin or a lighter complexion, having blue, green or other light coloured eyes and being older. In some rare cases, there is a faulty gene inherited which may be linked to several types of cancer in the family.

Symptoms

The symptoms of the different types of uveal melanoma can be difficult to pick up. This is because, unlike skin melanoma, you cannot see them. The exception is uveal melanoma in the iris that may appear as a dark area. They may be noticed by the optometrist during a routine eye test. Often, the first signs are discomfort in the eye. 

Possible symptoms you may see:

  • A new dark spot on the iris
  • A change in the size or the shape of your pupil (black area of the eye)
  • Blurred vision or other change in vision
  • Spots that drift in your field of vision
  • Flashes of light
  • A change in the position of your eyeball
  • Pain or discomfort in the eye

If your GP or optician cannot find another cause for these symptoms, you should be referred quickly (normally within about two weeks) to an ophthalmologist in a specialist hospital for tests and further evaluation.

uveal diagram

Diagnosis and staging

After a diagnosis of uveal melanoma, your medical team will work out the ‘stage’. The stage is a way of describing the key features of your melanoma and is helpful in guiding the best treatment and follow-up for you. Your stage provides an indication of how advanced your melanoma is. Generally, the higher the stage, the more advanced it is. 
Staging for uveal melanoma follows the American Joint Committee on Cancer (AJCC) Tumour, Node, and Metastasis (TNM) classification. Details of which can be found here.
We also have more information for patients on TNM staging on our site here.

Factors that can affect staging and prognosis include:

  • The location of the melanoma
  • The size of the melanoma
  • Whether the ciliary body has been involved
  • Whether the melanoma has started to grow outside of the eye or spread to other parts of the body, usually the liver (metastasis)

Biopsy

A biopsy is where a small amount of tissue is removed from within the eye (usually via a general anaesthetic) to be examined in the laboratory.  Most of the time, the diagnosis of uveal melanoma can be made without a biopsy, however, it may also be offered to help estimate the chances of the uveal melanoma from spreading.  Biopsies may be offered in the four main centres:  Liverpool, London, Sheffield and Glasgow.  For more information on biopsies, please download the full guide above.

Treatment

Surgery

The main treatment for a mucosal melanoma is surgery, which should be done by a surgeon who is very experienced in complex head and neck surgery. This is often in a specialised centre where there would be support from an experienced cancer team.

  • Surgery: minimising damage to the eye
  • Radiation therapy: These therapies target the melanoma with radiation
  • Phototherapy: This can involve a laser treatment that targets the melanoma with an infrared laser beam. Other types of phototherapy include the use of a dye in combination with a laser treatment

Tebentafusp 

Tebentafusp is the first and only licensed treatment  for patients with unresectable or metastatic uveal melanoma who test positive for HLA-A*02:01. Unresectable uveal melanoma is a tumour that cannot be surgically removed, and metastatic uveal melanoma is where the melanoma has spread to other parts of the body. The HLA test is a blood test to look at your immune type and, like your blood type, this doesn’t change with time. It is estimated that about 40-50% of the population are HLA-A*02:01-positive. If you test positive, tebentafusp may be a potential treatment for you.

Learn more about tebentafusp

 

We have worked with Dr Elaine Vickers to create a video which explains how Tebentafusp works and its use in the treatment of uveal melanoma. You can view that here.

Immunotherapy 

There are a number of other treatments such immunotherapy treatment available for uveal melanoma. None have been generally proven better than the another. We cover them in more detail in our Melanoma Stages and Treatment Patient Guide. 

Chemosaturation

If your uveal melanoma has spread to your liver only, you may be suitable for chemosaturation. Chemosaturation is where a high amount of anti-cancer chemotherapy is delivered directly to your liver under a general anaesthetic.  This is done by ‘sealing off’ the bloodstream to the liver from other parts of the body.  This ‘sealing off’ reduces the side-effects to the rest of your body, however, your blood count may be affected which could cause you to experience side effects such as getting infections, bruising easily or feeling tired or dizzy.

This treatment is currently available privately at the Spire in Southampton, the Christie Hospital in Manchester and the Harley Street Clinic in London, therefore you may need to travel for this treatment.  Once the final results from the clinical trial are published, an application will be made to NHS England to consider funding this treatment.  Not all insurers will fund the treatment and if you are self-paying, each treatment can cost in the region of £40,000. A minimum of two treatments are required and up to four treatments may be given in total, depending on how you respond and any side-effects you may experience.

Clinical Trials

The Melanoma TrialFinder aims to help you understand clinical trials and to empower you with information to discuss with your medical team. You can search for trials based on your location, your type of melanoma or the stage of your melanoma.

Melanoma TrialFinder

 

If you have any questions about your diagnosis or treatment, please call our:

Melanoma Helpline on 0808 801 0777

Surveillance

‘Surveillance’ is the term used when you are closely monitored post treatment so that any signs a disease has come back or spread may be detected as early as possible. At the end of treatment a plan should be put in place for ongoing surveillance which should include both the eye and potentially the liver (as there is a risk that uveal melanoma could spread to the liver). The chances of the uveal melanoma spreading outside of the eye may  be predicted which can help decide how you would be followed up. For more information on surveillance, please download the full guide above.

Patient Story

Victoria’s Story:

 

Victoria was diagnosed with stage 4 melanoma in 2019, after being diagnosed with primary ocular (uveal) melanoma in 2008. With the spread of the melanoma beyond her eye (also called secondary cancer), Victoria has undergone surgery and received  tebentafusp treatment on a clinical trial.

Read Victoria’s full story

Support: Facebook Groups

Ocular Melanoma UK run a number of online support groups hosted by Facebook, these groups are open to members of Ocular Melanoma UK, and have the privacy level “closed”, which means that only members of the group can see the posts. They have three main Facebook support groups, which include Ocular Melanoma UK Patient Group, Ocular Melanoma UK Family & Friends, Ocular Melanoma UK Bereaved Support. To find out more about these groups and how to join, click here.

Many people find it a huge comfort to connect with others in similar situations, however, we understand that this route of support does not benefit all as everyone’s experience is different. There is always the option to join the group and leave at a later point if your needs are not met.

Research invitation: Development of a quality of life questionnaire for people with metastatic uveal melanoma

Researchers at the University of Technology Sydney (UTS) and St Vincent’s Health Network would like to talk to individuals with metastatic uveal melanoma about impacts on quality of life from your illness and treatment.

They want to develop a questionnaire to measure these impacts in clinical trials so the benefits and side-effects from new treatments can be assessed to inform future care.

Participation will involve a 30-minute interview conducted via video conference (Zoom or Skype) in which you will be asked about impacts on quality of life and whether these are covered by existing questionnaires we will show you.

If you would like further information, please contact the co-ordinating investigator, Dr Tim Luckett, via tim.luckett@uts.edu.au

This study has been approved by the St Vincent’s Hospital Human Research Ethics Committee 2022/ETH01013

CURE OM Patient VISION Registry

This international registry is funded and sponsored by the Melanoma Research Foundation’s CURE OM initiative. The patient-reported ocular melanoma registry is an online database that securely collects, stores, monitors, analyses and shares data for research purposes. Open to patients and caregivers, registration is required and several personalised surveys to document diagnosis and treatment are requested. Participants can save their progress and continue the surveys at a future time and can revisit their records to update any changes.

Visit this link to find out more: https://melanoma.org/visionregistry/